Who are SB213503 lot 3's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SB213503 lot 2, SB213503 lot 1.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sb213503-lot-3.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

SB213503 lot 3 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SB213503 lot 3 (SB213503 lot 3) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CCR3 antagonist. Area: Respiratory/Immunology.

phase 3 CCR3 antagonist CCR3 Respiratory/Immunology Biologic Live · refreshed every 30 min

Target snapshot

SB213503 lot 3 (SB213503 lot 3) — GlaxoSmithKline. SB213503 is a selective antagonist of the chemokine receptor CCR3, which blocks eosinophil recruitment and activation in inflammatory airway diseases.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
SB213503 lot 3 TARGET	SB213503 lot 3	GlaxoSmithKline	phase 3	CCR3 antagonist	CCR3
SB213503 lot 2	SB213503 lot 2	GlaxoSmithKline	phase 3	CCR3 antagonist	CCR3 (C-C chemokine receptor type 3)
SB213503 lot 1	SB213503 lot 1	GlaxoSmithKline	phase 3	CCR3 antagonist	CCR3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CCR3 antagonist class)

GlaxoSmithKline · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SB213503 lot 3 — Competitive Intelligence Brief. https://druglandscape.com/ci/sb213503-lot-3. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab